MichaelWerner NikolausDeiningerMD
Hematology • Milwaukee, WIProfessor, Internal Medicine, University of Utah School of Medicine
Dr. Deininger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9200 W Wisconsin Ave
Milwaukee, WI 53226Phone+1 414-805-0505Fax+1 414-805-4606
Education & Training
University of Wurzburg Faculty of MedicineClass of 1990
Certifications & Licensure
CT State Medical License Current
WI State Medical License 2022 - 2025
OR State Medical License 2008 - 2023
UT State Medical License 2010 - 2022
Clinical Trials
- A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia Start of enrollment: 2011 Apr 01
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Start of enrollment: 2014 Jul 08
Publications & Presentations
PubMed
- 2 citationsA Bayesian framework to study tumor subclone-specific expression by combining bulk DNA and single-cell RNA sequencing data.Yi Qiao, Xiaomeng Huang, Philip J Moos, Jonathan M Ahmann, Anthony D Pomicter
Genome Research. 2024-02-07 - 28 citationsPonatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.Hagop M Kantarjian, Elias Jabbour, Michael Deininger, Elisabetta Abruzzese, Jane Apperley
American Journal of Hematology. 2022-11-01 - 61 citationsBosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.Tim H Brümmendorf, Jorge E Cortes, Dragana Milojkovic, Carlo Gambacorti-Passerini, Richard E Clark
Leukemia. 2022-07-01
Journal Articles
- Functional Genomic Landscape of Acute Myeloid LeukaemiaMarc M Loriaux, Christopher R Cogle, Patricia Kropf, Daniel A Pollyea, Uma Borate, Michael W Deininger, Nature
Lectures
- Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Extracting Diagnostic Data from Unstructured Bone Marrow Biopsy Reports of Myeloid Neoplasms Utilizing a Customized Natural Language Processing (NLP) AlgorithmClinical...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Pregnancy Outcomes in Patients Treated with Bosutinib2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Versiti Appoints Michael Deininger, MD, PhD, as Executive Vice President, Chief Scientific Officer and Director of Versiti's Blood Research InstituteApril 22nd, 2021- Proteasome 26S Subunit, Non-ATPases 1 (PSMD1) and 3 (PSMD3), Play an Oncogenic Role in Chronic Myeloid Leukemia by Stabilizing Nuclear Factor-Kappa BMarch 12th, 2021
The Chronic Myeloid Leukaemia Story in the United Kingdom Since 1960November 15th, 2020- Join now to see all
Grant Support
- Mechanisms Of Chronic Myeloid Leukemia Progenitor Cell SurvivalNational Cancer Institute2010–2011
- Ivis Spectrum Biophotonics InstrumentNational Center For Research Resources2009
- Biology Of Imatinib-Resistant Mutants Of BCR-ABLNational Heart, Lung, And Blood Institute2005–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
